| Autor: |
Martyn Frederickson, Christopher W. Murray, Neil T. Thompson, Tim Perera, Anne Cleasby, Eddy Jean Edgard Freyne, Ruth Feltell, Jose Cosme, Lynsey Fazal, Christopher Charles Frederick Hamlett, Michael Reader, Rajdeep Benning, Alistair O'Brien, Peter King, Darcey Miller, Matthew Squires, Patrick Angibaud, Andrew Madin, Valerio Berdini, Emma Vickerstaffe, Gordon Saxty, Brent Graham, Charlotte Griffiths Jones, Andrew Pike, Edward J. Lewis, Michael A. Batey, Douglas D. Ross, Susanne S. Bethell, Sharna J. Rich, Lindsay A. Devine, Maria Grazia Carr, Abarna Thiru, Julie Irving, George Ward, John Lyons, David R. Newell |
| Rok vydání: |
2011 |
| Předmět: |
|
| Zdroj: |
Molecular Cancer Therapeutics. 10:1542-1552 |
| ISSN: |
1538-8514
1535-7163 |
| DOI: |
10.1158/1535-7163.mct-11-0426 |
| Popis: |
We describe here the identification and characterization of 2 novel inhibitors of the fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases. The compounds exhibit selective inhibition of FGFR over the closely related VEGFR2 receptor in cell lines and in vivo. The pharmacologic profile of these inhibitors was defined using a panel of human tumor cell lines characterized for specific mutations, amplifications, or translocations known to activate one of the four FGFR receptor isoforms. This pharmacology defines a profile for inhibitors that are likely to be of use in clinical settings in disease types where FGFR is shown to play an important role. Mol Cancer Ther; 10(9); 1542–52. ©2011 AACR. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
